A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.
Age range
28 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Patients per Clinical Characteristic Category
Timeframe: Baseline
Clinical Characteristic: Time From FMF Diagnosis to Study Inclusion
Timeframe: Baseline
Clinical Characteristic: Time From the Start of Symptomatology to Study Inclusion
Timeframe: Baseline
Clinical Characteristic: Time From the Start of Symptomatology to FMF Diagnosis
Timeframe: Baseline
Clinical Characteristic: Age at the Start of Symptomatology
Timeframe: Baseline
Number of Patients by Symptomatology
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients by Characteristics of Relapses (Flares)
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare and Non-flare Related Inflammatory Marker Levels
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare and Non-flare Related Erythrocyte Sedimentation Rate (ESR)
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Flares per Month Since Last Visit
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare Duration Since Last Visit
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients With Recurrency of Flares at Diagnosis
Timeframe: Baseline
Number of Patients by Comorbidity
Timeframe: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients by Treatment Received Before FMF Diagnosis
Timeframe: Baseline
Number of Patients by Treatment Received At Least Once During the Study
Timeframe: Up to 11 years
Number of Patients by Treatment and Treatment Combinations Used at the end of the Study
Timeframe: Up to 11 years
Number of Patients Using Colchicine With Another Treatment at the end of the Study
Timeframe: Up to 11 years
Number of Patients by First Prescribed Colchicine Dose and Age Group
Timeframe: Up to 11 years
Number of Patients by Colchicine Maximum Global Dose and Age Group
Timeframe: Up to 11 years
Number of Patients With a Change in Colchicine Dose
Timeframe: Up to 11 years
Number of Patients by Reason for Stopping Colchicine Treatment and Age Group
Timeframe: Up to 11 years
Number of Patients by Anti-IL-1 Treatment Used at the end of the Study
Timeframe: Up to 11 years
Number of Patients by Anti-IL-1 Dose at the end of the Study
Timeframe: Up to 11 years
Number of Patients With a Change in Anti-IL-1 Dose
Timeframe: Up to 11 years
Number of Patients With a Change in Anti-IL-1 Treatment
Timeframe: Up to 11 years
Number of Patients by Reason for Stopping Anti-IL-1 Treatment
Timeframe: Up to 11 years